VivoSeq
Other

Mesenchymal Stem Cell Transplantation

0

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Mesenchymal Stem Cell Transplantation is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

17/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Unknown status2 · 33%
Terminated1 · 17%

Clinical Trials

Trial Activity

6 trials

Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis
Completed·RRoyan Institute·Phase 1·NCT01436058·6 enrolled
Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect
Completed·SShenzhen Hornetcorn Bio-technology Company, LTD·Phase 1·NCT02291926·20 enrolled
Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures
Completed·RRoyan Institute·Phase 2·NCT02140528·40 enrolled
Mesenchymal Stem Cell Transplantation in MS
Terminated·—·Phase 2·NCT01228266·9 enrolled
Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm
Unknown status·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT02853942·100 enrolled
Evaluating the Safety and Efficacy of Autologous Adipose Tissue-derived Mesenchymal Stem Cell Transplantation on Proinflammatory Cytokines and Anti-inflammatory Cytokines on Ageing-related Low-grade Inflammation Patients.
Unknown status·—·Phase 1/2·NCT05827757·72 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)